Metoclopramide Accord

Metoclopramide, the active ingredient in Metoclopramide Accord, is a dopamine D2 receptor antagonist presented as an oral tablet for oral use. It is employed to relieve nausea and vomiting, to promote gastric emptying in gastroparesis, and to aid symptom control in gastro‑oesophageal reflux disease.

GNH USA supplies Metoclopramide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide acts on the dopaminergic pathways that regulate nausea, vomiting and gastrointestinal motility. - Nausea and vomiting: reduces the frequency and severity of acute and chemotherapy‑induced episodes. - Gastroparesis: enhances gastric emptying and improves related digestive symptoms. - Gastro‑oesophageal reflux disease: supports lower oesophageal sphincter tone and decreases reflux episodes.

Metoclopramide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness - Fatigue - Restlessness or agitation - Diarrhoea - Headache - Insomnia

Serious or Rare Side Effects: - Extrapyramidal symptoms (e.g., dystonia, akathisia) - Tardive dyskinesia with prolonged use - Neuroleptic malignant syndrome - Severe depression or suicidal ideation - Seizures - Anaphylactic reactions

Before initiating therapy, clinicians should consider several safety measures. - Assess renal and hepatic function: adjust use in impairment. - Use caution in patients with Parkinson's disease or other movement disorders. - Avoid in individuals with known hypersensitivity to metoclopramide. - Monitor for signs of depression, suicidal thoughts, or severe anxiety. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metoclopramide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Central nervous system depressants (e.g., benzodiazepines, opioids): additive sedation. - Drugs that prolong QT interval: increased risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): may raise metoclopramide plasma levels. - Anticholinergic agents: may reduce pro‑kinetic efficacy. - Antidepressants (SSRIs, SNRIs): potential for serotonin syndrome when combined with other serotonergic drugs.